Document 71881L5XY4edRDKk3JqRyooYE
Link between the firefighting foam restriction and the wide PFAS restriction
FPP4EU
15 June 2022
Peter SIMPSON Restriction Process Coordinator European Chemicals Agency
Image: iStock.com
Overview
PFAS risk management in the EU Justification for grouping PFASs Links to wide restriction
Hazard/risk paradigm Practicality Some frequently asked questions
Next steps
2
Existing regulation of PFASs in EU
Some PFAS already subject to [or pending] restrictions on manufacture/use under REACH or POPs regulation in EU (some also Stockholm Convention)
Perfluoroalkyl sulfonic acids (PFOS; [PFHxS]) Perfluoroalkyl carboxylic acids (PFOA; C9-C14 PFCAs; [PFHxA])
Some identified as SVHCs
E.g. HFOP-DA (GenX), PFBS, PFHxS
Some undergoing REACH substance evaluation or have a harmonised classification under CLP regulation
3
Arrowhead approach
Risk management has typically focused on `arrowheads' with confirmed hazard properties and their `precursors'
Arrowheads - terminal degradation product
typically PBT/vPvB properties e.g. PFOA, PFHxS, C9-C14 PFCAs
`Precursors' or `related-substances' transform to arrowhead
A single restriction can cover many different substances as long as they contain the arrowhead moiety
Effective but slow and can result in a cascade of regrettable substitution
PFOS PFOA PFHxA ????
4
Mandate
Request 20 July 2020 Assess PFASs as a group Build on previous studies
on availability of alternatives Cooperate with authorities working on PFAS restriction Submission January 2022
5
PFASs in firefighting foams
Around 18 000 tonnes of PFAS firefighting foams sold in the EU each year
500 tonnes of PFAS Oil/(petro-)chemical sector is the
largest user Most sectors have examples of
users that have substituted to fluorine-free foams (typically training)
6
PFASs as a group
Boundaries by OECD definition (2021) Structural similarity
Perfluorinated moieties
Any substance that contains at least one fully fluorinated methyl (CF3) or methylene (CF2) carbon atom (without any H/Cl/Br/I attached to it)
Single hazard/risk paradigm
Developed by DE, NL, DK, SE, NO Ice-breaker in firefighting foams Includes fluoropolymers/F-gases
Avoid regrettable substitution
https://pubs.acs.org/doi/pdf/10.1021/acs.est.1c06896
7
Hazard/risk paradigm
PFASs assessed as a group
Persistence is the common property of the group
Various supporting concerns
8
Properties
Very high persistence
Long-range transport potential
Mobility
Accumulation in plants
Bioaccumulation potential
Endocrine activity
Ecotoxicity
Effects to human health
Hazard/risk paradigm
PFASs are among the most stable organic compounds
Resist (bio) degradation because of the stable C-F bond
Many PFASs can be transported by air, water and matrices to which they are adsorbed or absorbed
e.g., dust, sediments, migratory animals and polymer particles
Many PFASs are ubiquitous in environmental compartments and biota (e.g. mammals, birds, fish)
Plants accumulate many PFASs beyond expected levels Exposures may be higher than observed by monitoring For well studied PFASs effects on behaviour, growth, reproduction,
metabolism, organs & immune system observed In silico, in vitro and in vivo data provide indications of interactions of
various PFASs with the endocrine system Harmonised class. for PFOS, PFOA, PFNA, and PFDA (+ salts):
carcinogenicity (Carc. 2), reproductive toxicity (Repr. 1B), effects on or via lactation (Lact.), specific target organ toxicity - repeated exposure (STOT RE 1).
Hazard/risk paradigm
Persistence combined with supporting concerns
Quantitative risk assessment is not reliable or practicable Not possible to demonstrate safe use (no reliable DNEL/PNEC)
Similar to PBT/vPvB
Continued use would inevitably result in accumulation to levels causing adverse effects
`Case-by-case' risk assessment according to Annex I (section 0.1) of REACH
Risks of PFASs are considered as non-threshold and not adequately controlled
Releases are a proxy for uncontrolled risk Risk management to minimise releases
10
Practicality
Concentration limit of 1 ppm PFASs Expressed as `total organic fluorine' Presence and concentration of non-PFAS
organofluorine substances shall be included on the product packaging Practical enforcement despite structural variability
11
Common questions
Common questions (1)
Scope (which substances are in/out?)
Is analysis of degradation products (arrowheads) needed before a substance is within scope?
No, the scope is set by the OECD definition
Is substance-specific information on hazards or case-by case assessment of risks needed?
No, the hazard / risk conclusion is applicable to the whole group, irrespective of substance-specific information (no threshold)
Evidence to consider PFAS as non-persistent (OECD?)
RAC/SEAC and DS will assess justifications case-by-case
Will scope be based on PFASs used in firefighting foams?
No, intention is to prevent regrettable substitution - whole lifecycle
13
Common questions (2)
Existing OCs and RMMs
Is existing legislation sufficient to address the identified risks (e.g. IED / OSH / F-gas)
No, Annex XV report concludes existing measures are not sufficient to control the identified risk
DS notes that regulatory baseline is dynamic Commission would need to reconcile any overlaps
What measures could be put in place?
Risk management objective is minimisation of risk Restriction can apply to a minimised risk - if proportionate; is
restriction disproportionate?
14
Common questions (3)
Exports
Restriction applies use (e.g., formulation)
Justified based on risks at this lifecycle stage (releases) Restriction prevents formulation for export Socio-economic analysis refers to impacts on exports DS will revise text after the consultation to prevent
misinterpretation
15
Next steps
https://www.echa.europa.eu/-/eu-restriction-of-per-andpolyfluoroalkyl-substances-pfas-in-firefighting-foams
Next steps
Proposal being evaluated by ECHA's committees for:
Risk Assessment (RAC) Socio-Economic Analysis (SEAC)
Six-month consultation of interested parties
Stakeholder information session 5 April Q&A published on ECHA website 15 June
Evaluation documented in `opinions' Commission and Member States decide on
implementing the restriction in REACH Committee Scrutiny by Council and European Parliament
17
NECHA EUROPEAN CHEMICALS AGENCY
Thank you!
echa.europa.eu